Modus Therapeutics (Sweden) Price Prediction
| MODTX Stock | 0.34 0.01 2.86% |
Momentum 49
Impartial
Oversold | Overbought |
Using Modus Therapeutics hype-based prediction, you can estimate the value of Modus Therapeutics Holding from the perspective of Modus Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Modus Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Modus because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Modus Therapeutics after-hype prediction price | SEK 0.34 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Modus |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Modus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Modus Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Modus Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Modus Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Modus Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Modus Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Modus Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Modus Therapeutics' historical news coverage. Modus Therapeutics' after-hype downside and upside margins for the prediction period are 0.02 and 5.12, respectively. We have considered Modus Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Modus Therapeutics is out of control at this time. Analysis and calculation of next after-hype price of Modus Therapeutics is based on 3 months time horizon.
Modus Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Modus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Modus Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Modus Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.36 | 4.78 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
0.34 | 0.34 | 0.00 |
|
Modus Therapeutics Hype Timeline
Modus Therapeutics is now traded for 0.34on Stockholm Exchange of Sweden. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. Modus is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is now at -0.36%. %. The volatility of related hype on Modus Therapeutics is about 0.0%, with the expected price after the next announcement by competition of 0.34. About 79.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.57. Modus Therapeutics had not issued any dividends in recent years. Assuming the 90 days trading horizon the next projected press release will be uncertain. Check out Modus Therapeutics Basic Forecasting Models to cross-verify your projections.Modus Therapeutics Related Hype Analysis
Having access to credible news sources related to Modus Therapeutics' direct competition is more important than ever and may enhance your ability to predict Modus Therapeutics' future price movements. Getting to know how Modus Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Modus Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| EXPRS2 | ExpreS2ion Biotech Holding | 0.00 | 0 per month | 0.00 | (0.04) | 5.27 | (6.89) | 36.96 | |
| 2CUREX | 2cureX AB | 0.00 | 0 per month | 0.00 | (0.37) | 5.30 | (8.26) | 24.79 | |
| AINO | Aino Health AB | 0.00 | 0 per month | 7.39 | 0.01 | 20.00 | (19.05) | 50.25 | |
| GUARD | Guard Therapeutics International | 0.00 | 0 per month | 0.00 | (0.16) | 8.09 | (10.37) | 99.81 | |
| EPIS-B | Episurf Medical AB | 0.00 | 0 per month | 0.00 | (0.08) | 6.76 | (6.87) | 24.28 | |
| STABL | Stayble Therapeutics AB | 0.00 | 0 per month | 5.84 | 0.01 | 14.81 | (10.00) | 63.79 | |
| SIMRIS-B | Simris Alg AB | 0.00 | 0 per month | 0.00 | (0.09) | 9.09 | (13.63) | 28.87 | |
| FLUI | Fluicell AB | 0.00 | 0 per month | 0.00 | (0.06) | 8.33 | (8.11) | 31.42 | |
| QLIFE | Qlife Holding AB | 0.00 | 0 per month | 4.77 | 0.02 | 13.97 | (6.59) | 34.49 | |
| LPGO | Lipigon Pharmaceuticals AB | 0.00 | 0 per month | 0.00 | (0.21) | 7.69 | (11.64) | 97.42 |
Modus Therapeutics Additional Predictive Modules
Most predictive techniques to examine Modus price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Modus using various technical indicators. When you analyze Modus charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Modus Therapeutics Predictive Indicators
The successful prediction of Modus Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Modus Therapeutics Holding, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Modus Therapeutics based on analysis of Modus Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Modus Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Modus Therapeutics's related companies.
Story Coverage note for Modus Therapeutics
The number of cover stories for Modus Therapeutics depends on current market conditions and Modus Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Modus Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Modus Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
Modus Therapeutics Short Properties
Modus Therapeutics' future price predictability will typically decrease when Modus Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Modus Therapeutics Holding often depends not only on the future outlook of the potential Modus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Modus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 12.4 M | |
| Cash And Short Term Investments | 20.6 M |
Additional Tools for Modus Stock Analysis
When running Modus Therapeutics' price analysis, check to measure Modus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Modus Therapeutics is operating at the current time. Most of Modus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Modus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Modus Therapeutics' price. Additionally, you may evaluate how the addition of Modus Therapeutics to your portfolios can decrease your overall portfolio volatility.